NCT05839600View on ClinicalTrials.gov

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 7, 2023

Primary Completion Date

April 10, 2025

Study Completion Date

April 10, 2025

Conditions
Solid Tumors
Interventions
DRUG

BI 1821736

Solution for infusion

Trial Locations (7)

17177

Karolinska Universitetssjukhuset Stockholm, Stockholm

28041

Hospital Universitario 12 de Octubre, Madrid

46009

Instituto Valenciano de Oncología, Valencia

78229

NEXT Oncology-San Antonio-65273, San Antonio

06511

Yale Cancer Center, New Haven

M5G 2M9

Princess Margaret Cancer Centre, Toronto

08036

Hospital Clínic de Barcelona, Barcelona

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05839600 - A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | Biotech Hunter | Biotech Hunter